Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nabiximols crossover trial for multiple sclerosis spasticity
2019-002625-29Phase 3Completed
- Sponsor
- GW Pharmaceuticals
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cannabidiol in multiple sclerosis (MS) and Muscle spasm (2 arms), sponsored by GW Pharmaceuticals. Primary endpoint: Change in Lower Limb Muscle Tone-6. Started Nov 2019; status: completed.
02
Drugs
cannabidiol
03
Conditions
multiple sclerosis (MS)Muscle spasm
Beyond the preview
Go deeper on 2019-002625-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002625-29.